Evolution Research Group acquires Richmond Behavioral Associates

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/whitehoune)
(Image: Getty/whitehoune)

Related tags: Clinical trials, depression, acquisition

The acquired company specializes in conducting clinical trials for depression, anxiety, bipolar disorder and other central nervous system conditions.

Evolution Research Group (ERG) is an independent clinical research site company based in New Providence, NJ; it focuses on neuroscience and special populations. Acquiring Richmond Behavioral Associates (RBA), a Staten Island, NY clinical trial organization, will enable the firm to broaden its capabilities, covering both adult and pediatric populations.

Andria Chastain, COO for ERG, said taking on RBA will enable the company to expand its footprint in the New York region. Of RBA, she said, “Their history of delivering quality results in complex outpatient trials, particularly in children and adolescents, expands our capacity​.”

Chastain added that the acquisition complements the capabilities of its various teams, including its inpatient pediatric pharmacokinetics unit.

Adam Smith, an investigator with RBA, said, “The opportunity for growth and expansion in our geographic region is undeniable and, given ERG's excellent reputation in the industry and their proven track record of growing portfolio sites, our investigators…firmly believe that ERG is the perfect partner to take our site to the next level​."

Michael Farah, ERG chairman and partner at Linden Capital Partners, said RBA has a strong strategic growth plan, which will enable his firm to “further service our deep client base and continue to assist in the development of important new therapies​."

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more